FDA Grants AP Status for Lamotrigine ANDA078982 by Granules
The FDA has granted approval status (AP) for the ANDA078982 application for Lamotrigine submitted by Granules.
Published: August 2, 2026
Updated: August 2, 2026
Author: Humanexa Intelligence
Therapeutic area: Neurology / Antiepileptic
Asset: Granules
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Asset
Granules
Indication
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The FDA's approval of Granules' Lamotrigine ANDA078982 is significant as it enhances competition in the generic antiepileptic market. This could impact market dynamics, pricing strategies, and market share for existing branded products.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor the launch timeline and market entry of Granules' Lamotrigine product, as well as competitor responses.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.